The bill directs the Secretary of Health and Human Services, acting through the FDA Commissioner, to establish a standard of identity for individual olive oil grades and to publish grade standards for olive oil and olive‑pomace oil used in commerce. Those grade standards must specify quality and purity parameters, acceptable analytical methods, and mandatory labeling rules tied to grade names.
This matters because, if adopted, the standards become the statutory basis for treating nonconforming products as misbranded under the Federal Food, Drug, and Cosmetic Act. For producers, packers, importers, and retailers, the bill creates a single, enforceable U.S. benchmark for grade names and testing that has implications for labeling, supply‑chain testing, and marketing claims.
At a Glance
What It Does
The bill requires FDA to (1) establish a standard of identity under section 401 of the FD&C Act for individual olive oil grades and (2) publish grade standards for specified olive oil and olive‑pomace oil categories that set quality/purity parameters, authorize recognized analytical methods, and impose mandatory labeling requirements. It also mandates a report to Congress within 120 days of enactment on actions taken.
Who It Affects
Commercial olive oil producers, packers, importers, and marketers who label or sell olive oil or olive‑pomace oil in the United States; laboratories and accreditation bodies that perform oil analyses; and retailers that present grade claims on packaging. FDA will carry primary implementation responsibility.
Why It Matters
By tying grade names to a federal standard of identity and specific analytical methods, the bill gives regulators a clearer enforcement hook against mislabeled oils and creates a consistency point that could change labeling and testing practices across the supply chain. It also aligns U.S. requirements with internationally recognized testing standards as the bill contemplates.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill tasks FDA with two related deliverables. First, FDA must draft a standard of identity under the FD&C Act that defines each named grade of olive oil — effectively describing what an ‘‘extra virgin’’ or ‘‘refined olive‑pomace oil’’ must be to lawfully carry that name.
Second, FDA must set grade standards for a defined list of olive oil and olive‑pomace oil categories. Those standards are not freeform: the statute requires quality and purity parameters, a set of accepted analytical methods, and mandatory labeling rules consistent with specified parts of the federal labeling regulations.
On testing, the bill explicitly anchors acceptable methods to established accreditation systems — the American Oil Chemists’ Society (AOCS), International Organization for Standardization (ISO), or International Olive Oil Council (IOC) methods. That means FDA is expected to rely on laboratory procedures and accreditation recognized in the industry when it defines how to measure acidity, peroxide values, oxidative markers, and other characteristics.
For the extra virgin grade, the bill names two specific chemical markers — pyropheophytin a (PPP) and 1,2‑diacylglycerols (DAG) — that FDA must include in quality parameters, reflecting industry concerns about freshness and refining.The labeling component requires that product names match the grade established and that package descriptions avoid ‘‘inappropriate and misleading messages.’’ The bill cross‑references several parts of current FDA labeling rules, so final packaging rules will need to reconcile the new grade definitions with existing nutrition, identity, and country‑of‑origin labeling requirements. Finally, the statute compels FDA to report to Congress within 120 days of enactment on what it has done under the law, creating a fast window for initial guidance or proposed rulemaking.
The Five Things You Need to Know
The bill directs FDA to establish a standard of identity under 21 U.S.C. 341 for individual olive oil grades.
FDA must publish grade standards covering eight categories: extra virgin, virgin, olive oil, refined olive oil, lampante, olive‑pomace oil, refined olive‑pomace oil, and crude olive‑pomace oil.
Accepted analytical methods must be tied to AOCS, ISO, or IOC accreditation procedures rather than ad hoc lab tests.
Quality parameters for extra virgin olive oil must include pyropheophytin a (PPP) and 1,2‑diacylglycerols (DAG) measurements.
FDA must transmit a report to Congress on actions taken under the section within 120 days of the bill’s enactment.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title — 'Olive Oil Standards Act'
This single‑line provision gives the bill its short name and has no substantive effect on duties or timelines. It matters administratively because future references to the implementing actions and any subsequent rulemakings will cite this act.
Standard of identity under the FD&C Act
Mandates that FDA write a standard of identity for each individual olive oil grade under section 401 of the FD&C Act. A standard of identity, once established, means that products not meeting that definition may be considered misbranded. Practically, this converts descriptive grade names into enforceable legal definitions rather than advisory industry terms.
Grade standards for commerce — scope and required contents
Requires FDA to set grade standards for commercial producers, bottlers, and marketers and specifies three content pillars: (i) quality and purity parameters tailored to each named grade; (ii) methods of analysis tied to AOCS, ISO, or IOC accreditation methods; and (iii) mandatory labeling rules consistent with specified parts of Title 21 CFR. For compliance teams, this means the grade framework will address both chemical/analytical thresholds and the wording and presentation allowed on packaging.
Special rules — extra virgin markers and labeling fidelity
Directs FDA to include PPP and DAG parameters in the extra virgin quality profile and to ensure labeling names and package descriptions are consistent with the established grades and not misleading. The explicit marker requirement pushes regulators to adopt tests that distinguish fresh, unrefined oils from oils that have been heated or adulterated — a technical decision with downstream effects on labs, sampling protocols, and market claims.
Congressional report requirement
Requires FDA to transmit a report to Congress within 120 days of enactment describing actions taken under the section. This short deadline likely forces FDA to publish at least an implementation plan, interim guidance, or proposed rule rather than a final, fully vetted rule, and it creates an early transparency checkpoint for industry and oversight committees.
This bill is one of many.
Codify tracks hundreds of bills on Agriculture across all five countries.
Explore Agriculture in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Quality olive oil producers (domestic and compliant importers): will gain a clear, enforceable definition of grade names that protects premium labeling and reduces unfair competition from mislabeled or adulterated products.
- Retailers and brands that emphasize provenance and grade accuracy: receive a consistent framework to verify supplier claims and reduce customer disputes and returns.
- Accredited testing laboratories and certification bodies: stand to gain increased demand as the bill ties compliance to recognized analytical and accreditation methods.
- Consumers seeking reliable labeling: will have a statutory basis to expect consistency in what ‘‘extra virgin’’ and other grade descriptors mean on U.S. shelves.
Who Bears the Cost
- Low‑margin importers and producers using blended or lower‑grade oils: may face retooling costs, relabeling, or loss of ability to market products under certain grade names if they do not meet the new standards.
- Small producers and craft bottlers: could incur testing, recordkeeping, and labeling compliance costs that are proportionally larger than for larger firms.
- FDA (HHS) and state enforcement agencies: will need resources to draft the standards, issue guidance, and enforce compliance, especially given the 120‑day reporting deadline.
- Non‑accredited laboratories and informal testing providers: may face decreased relevance unless they obtain accreditation aligned with AOCS/ISO/IOC methods.
Key Issues
The Core Tension
The bill balances two legitimate goals — protecting consumers and honest producers by giving grade names legal force, versus imposing technical testing and labeling burdens that could disadvantage smaller producers and complicate international trade; enforcing precise chemical thresholds helps deter fraud but creates implementation and cost hurdles that FDA must manage carefully.
The bill sets technical direction without spelling out enforcement mechanics, sampling protocols, or transitional timelines: it creates a legal definition and references accreditation bodies, but it leaves FDA to resolve how to operationalize testing frequency, sample selection, and dispute processes. That gap raises practical questions — for example, how will FDA treat legacy inventories that were labeled before new standards take effect, and what tolerances will FDA allow for natural variability across harvests and cultivars?
Tying methods to AOCS, ISO, or IOC accreditation narrows analytical flexibility but also raises trade and equivalence issues. International suppliers that comply with IOC rules may still face interpretation disputes if U.S. thresholds or marker cutoffs differ.
Moreover, requiring chemical markers like PPP and DAG for extra virgin status strengthens freshness/refining tests but also increases testing complexity and cost; smaller operators may struggle to meet accreditation or to fund routine testing, potentially shrinking the pool of suppliers who can lawfully use grade names.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.